Inspection ended with zero observation under form 483
Cadila Healthcare, a global pharmaceutical company that discovers, develops, manufacturers and markets a broad range of healthcare therapies, has announced that the US FDA inspected its API manufacturing facility at Dabhasa, Gujurat from January 15 to 19, 2018. At the end of the inspection, no observation (483) was issued.
- Advertisement -
Comments are closed.